Home » Topics » Drugs » Immuno-oncology

Immuno-oncology
RSS

Novel duocarmycin derivative suitable for use in anticancer immunoconjugates

Sep. 15, 2000

NCI sponsors additional phase II studies of Prostvac VF vaccine

Sep. 13, 2000

StressGen commences phase II trial of HspE7 for treatment of cervical cancer

Sep. 12, 2000

Maxamine granted priority FDA review for melanoma

Sep. 8, 2000

Herceptin approved in E.U. for treatment of HER2-positive metastatic breast cancer

Aug. 30, 2000

Cancer vaccine shows potential for decreasing risk of relapse and death

Aug. 30, 2000

LifeTime Pharmaceuticals announces U.S. phase I/II trials of Beta LT for cancer

Aug. 29, 2000

Cel-Sci to commence phase II Multikine study in Czech Republic

Aug. 24, 2000

Ilex and Millennium respond to FDA letter on Campath

Aug. 24, 2000

Bioniche reports preclinical findings for MCC in prostate cancer

Aug. 21, 2000

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 16, 2026.
AAIC 2026: Age of amyloid is being joined by time of tau
BioWorld
The Alzheimer’s Association International Conference (AAIC) is the world’s biggest dementia conference. And at the AAIC 2026 meeting, there is big buzz around...
Celia trial: data strong, analysts skeptical
BioWorld
Tuesday brought what was arguably the most anticipated presentation of the 2026 Alzheimer’s Association International Conference when Catherine Mummery, head of...
News in brief
BioWorld Asia
BioWorld Asia briefs for July 14, 2026
Voyager’s gene therapy reduces tau levels in AD models
BioWorld Science
At the Alzheimer’s Association International Conference, researchers from Voyager Therapeutics Inc. presented preclinical efficacy data for VY-1706, a blood-brain...